Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a Healthcare company (Medical - Devices) with a market capitalization of $568M. The Maz Rating grades it against the other companies in its sector.
Pacific Biosciences of California, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.82, Pacific Biosciences of California, Inc. trades at 3.6x sales. Over the last twelve months it generated about $159M of revenue and a net loss of $129M. It runs a gross margin of 34.5%, an operating margin of -99.6% and a net margin of -81.3%. It shows return on equity of 604.2%, return on invested capital of -24.5% and a free cash flow yield of -33.1%. On the balance sheet: a debt-to-equity ratio of -11.49 and a current ratio of 4.62. Over the past 52 weeks the share price ranged from $1.07 to $3.44, with a beta of 2.20.
Pacific Biosciences of California, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 9 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Pacific Biosciences of California, Inc. (PACB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 111.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 34.5% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 111.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.5% / 33% · Receivables / Mkt Cap (36m) 6.63% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 111.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.5% / 33.33% · Receivables / Mkt Cap (24m) 6.63% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 86.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 32.6% / 33.33% · Receivables / Avg Assets (4Q) 4.42% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 89.2% / 33.33% · (Cash+ST Inv) / Total Assets 27.7% / 33.33% · (Cash+Recv) / Total Assets 33.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Pacific Biosciences of California, Inc. (PACB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Pacific Biosciences of California, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Pacific Biosciences of California, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.